bêta
IA Trial Radar
L'essai clinique NCT06377254 (CHAIN) pour Comportement sédentaire, Syndrome métabolique, Déclin cognitif lié à l'âge, Sarcopénie liée à l'âge est en recrutement. Consultez la vue en carte du Radar des Essais Cliniques et les outils de découverte par IA pour tous les détails, ou posez vos questions ici.
Un essai clinique correspond aux filtres sélectionnés
Vue en carte

Multi-organ Responses to CHronic Physical Activity and INactivity (CHAIN)

En recrutement
Les détails de l'essai clinique sont principalement disponibles en anglais. Cependant, l'IA Trial Radar peut vous aider ! Cliquez simplement sur 'Expliquer l'essai' pour voir et discuter des informations sur l'essai dans la langue sélectionnée.
L'étude clinique NCT06377254 (CHAIN) est un essai interventionnel pour Comportement sédentaire, Syndrome métabolique, Déclin cognitif lié à l'âge, Sarcopénie liée à l'âge. Son statut actuel est : en recrutement. L'étude a débuté le 12 mars 2024 et vise à recruter 40 participants. Dirigé par University of Nottingham, l'essai devrait être terminé d'ici le 31 octobre 2028. Les données du site ClinicalTrials.gov ont été mises à jour pour la dernière fois le 28 août 2025.
Résumé succinct
Life expectancy has been increasing for the last 150 years, but the maintenance of health has not kept pace with increased lifespan, and on average, UK adults spend the last decade of life in poor-health, with major consequences for society and the individual.

Persistent physical inactivity is thought to be a key contributing factor to the risk of poor health and functional decline occurring in middle-aged and older adults. It is therefore concerning that most middle-aged adults spend >8hrs/day being sedentary, with average step count of 3000-4000 steps/day.

To be able to holistically assess the effectiveness of future strategies to address age-related decline in health, and devise public health messages to help individuals reach older age in better health, it is essential that the complex physiological effects that activity and inactivity have across biological systems are characterised.

The goal of this intervention study is to compare the impact of physical activity and inactivity on body functioning. Twenty moderately active participants will decrease their physical activity for three months to match the average amount carried out by middle-aged people in the UK. They will then undertake 3-months of reconditioning training to restore their fitness. In addition, twenty sedentary participants will increase their physical activity to UK recommended levels for six months.

Before and at points during the intervention period, participants will be asked to make some measurements at home and attend the University of Nottingham to have multiple assessments made. These include;

  • fitness, muscle strength and function tests,
  • completion of questionnaires and computer-based brain puzzles
  • having muscle and fat tissue biopsies and blood samples taken.
  • The study also involves having MRI scans.

This 5-year study will commence in January 2024, with participant recruitment starting in March 2024 and finishing in May 2027.

Description détaillée
This is a parallel design study comparing the impact of physical activity and inactivity on the way the body functions, to understand the mechanisms (including the inter-relationship between tissues and organs) by which lifestyle behaviours may effect health and wellbeing in later life. In particular, the mechanisms by which inactivity results in long term poor health is not well understood, and has rarely been studied in an integrated way in people. However, initial research indicates that the physiology of being inactive is not simply the reverse of being active. To enable effective treatments and public health advice to be devised so that more adults reach old age in better health, and maintain a good quality of life for a greater proportion of their older age, it is important that the impact of physical inactivity on the way the body functions is better understood. Therefore, twenty participants who are moderately, but not highly active will be asked to decrease their physical activity for three months to match the average exercise levels of middle-aged people in the United Kingdom (UK). This will require them to increase their daily sitting time to 7 hours a day and reduce their step count to <4500 steps per day. At the end of the 3-months they will undertake 3-months of supervised reconditioning training by attending the Medical School at Queen's Medical Centre, Nottingham, three times a week.

In addition, twenty participants who currently have low physical activity levels will be asked to increase their physical activity to UK recommended levels by attending the Medical School at Queen's Medical Centre, Nottingham, three times a week for six months to undertake a supervised exercise program.

Before and during the 6-month period (at weeks 6, 12, 18 and 24) participants will be asked to make some measurements at home (physical activity levels, dietary intake) and attend the University of Nottingham over 4 days to have multiple assessments made. These include: height; weight; body composition (body fat and lean tissue); blood pressure; fitness, muscle strength and function; sleep quality, quality of life and wellbeing (questionnaires). The rate of muscle protein breakdown and muscle protein synthesis, blood sugar regulation, and biochemistry of the blood, fat tissue and muscles will be assessed, and to enable this muscle and fat tissue biopsies will be collected and blood samples taken. The study also involves having MRI scans to study the structure and function of the brain and heart, and to determine liver and muscle fat content.

Titre officiel

Concurrent Multi-organ Responses to CHronic Physical Activity and INactivity Intervention, to Increase Research Discovery in Human Health and Wellbeing

Conditions
Comportement sédentaireSyndrome métaboliqueDéclin cognitif lié à l'âgeSarcopénie liée à l'âge
Autres identifiants de l'essai
  • CHAIN
  • BB/X015173/1
Numéro NCT
Date de début (réel)
2024-03-12
Dernière mise à jour publiée
2025-08-28
Date de fin (estimée)
2028-10-31
Inscription (estimée)
40
Type d'essai
Interventionnel
PHASE
N/A
Statut
En recrutement
Mots clés
Physical activity
middle-age
Physical inactivity
overweight
lifestyle
Objectif principal
Recherche fondamentale
Plan d'attribution
Non aléatoire
Modèle d'intervention
Parallèle
Masquage
Simple aveugle
Bras / Interventions
Groupe de participants/BrasIntervention/Traitement
ExpérimentalInactivity
Participants in this group will reduce their physical activity (increase sitting time to 7hrs/day and decrease step count to \<4500/day) for 3 months, then increase their activity for 3 months, through attending 3x 45 min supervised exercise sessions/week.
Decreased Physical Activity
Physical activity levels will be decreased
ExpérimentalActivity
Participants in this group will have moderate intensity physical activity levels increased for 6 months, through attending 3x 45 min supervised exercise sessions/week.
Increased Physical Activity
Physical activity levels will be increased
Critère principal d'évaluation
Critères d'évaluationDescription de critèresPériode
Change in Cardiorespiratory fitness (VO2 max)
change in maximal oxygen uptake (continuous incremental bicycle ergometer exercise test with on-line gas analysis) measured every 6 weeks
12 weeks
Critère secondaire d'évaluation
Critères d'évaluationDescription de critèresPériode
Change in Isometric leg strength
Change in Isometric leg strength measured every 6 weeks using CYBEX dynamometer
24 weeks
Change in time to leg fatigue
Change in time taken to induce muscle fatigue measured every 6 weeks using isokinetic knee extensions on a CYBEX dynamometer
24 weeks
Change in incremental area under the curve (iAUC) for blood glucose concentration
Change in 180 minute blood glucose concentration incremental area under the curve measured every 6 weeks during an oral glucose tolerance test.
24 weeks
Change in iAUC for serum insulin concentration
Change in 180-minute serum insulin concentration incremental area under the curve measured every 6 weeks during an oral glucose tolerance test
24 weeks
Change in fasting glucose oxidation rate
Change in glucose oxidation rate (when fasted), measured every 6 weeks using ventilated hood indirect calorimetry
24 weeks
Change in 'fed' glucose oxidation rate
Change in glucose oxidation rate (in the insulin-stimulated 'fed' state), measured every 6 weeks using ventilated hood indirect calorimetry during an oral glucose tolerance test
24 weeks
Change in Short Form Health Survey (SF36) Questionnaire aggregated normalised 'physical' score
Change in 'SF36' Questionnaire aggregated 'physical' score (normalised to UK population) calculated according to standard procedures (min 0, max 100), with higher score indicating better physical wellbeing measured every 6 weeks
24 weeks
Change in Short Form Health Survey (SF36) Questionnaire aggregated and normalised 'mental' score
Change in 'SF36' Questionnaire aggregated 'mental' score (normalised to UK population) calculated according to standard procedures (min 0, max 100), with higher score indicating better mental wellbeing, measured every 6 weeks
24 weeks
Change in World Health Organisation Quality of Life (WHOQoL) score
Change in World Health Organisation Quality of Life Score (measured using the WHOQoL-Bref questionnaire every 6 weeks), (min score 0, max 100), with higher score indicating a better state of health.
24 weeks
Change in Pittsburgh Sleep Quality Index (PSQI)
Change in PSQI score (min score 0, max 21), measured every 6 weeks, with higher score indicating poorer sleep quality
24 weeks
Change in Stroop test; % Accuracy
Change in the percentage of accurate responses, measured every 6 weeks, with higher score indicating better cognitive performance. Minimum value 0%, maximum value 100%
24 weeks
Change in Stroop test; reaction time
Change in the reaction time for responses, measured every 6 weeks, with higher score indicating slower cognitive performance. No minimum or maximum value defined.
24 weeks
Change in four-choice reaction time test; % Accuracy
Change in the percentage of accurate responses, measured every 6 weeks, with higher score indicating better cognitive performance. Minimum value 0%, maximum value 100%
24 weeks
Change in four-choice reaction time test; reaction time
Change in the reaction time for responses, measured every 6 weeks, with higher score indicating slower cognitive performance. No minimum or maximum value defined.
24 weeks
Change in card sort test; % Accuracy
Change in the percentage of accurate responses, measured every 6 weeks, with higher score indicating better cognitive performance. Minimum value 0%, maximum value 100%
24 weeks
Change in card sort test; reaction time
Change in the reaction time for responses, measured every 6 weeks, with higher score indicating slower cognitive performance. No minimum or maximum value defined.
24 weeks
Change in Logical reasoning test; % accuracy
Change in the accuracy of responses, measured every 6 weeks, with higher score indicating better cognitive performance. Minimum value 0%, maximum value 100%
24 weeks
Change in Logical reasoning test; reaction time
Change in the reaction time for responses, measured every 6 weeks, with higher score indicating slower cognitive performance. No minimum or maximum value defined.
24 weeks
Change in serial subtractions test; number of responses in 2 minutes
Change in the number of responses, measured every 6 weeks, with higher score indicating better cognitive performance. minimum number is 0, maximum number is variable dependent on starting value (800-999; randomly selected by computer program) and speed of response.
24 weeks
Change in Corsi blocks test; score
Change in the test score, measured every 6 weeks, with higher score indicating better cognitive performance.Minimum score is 0 and maximum is 15.
24 weeks
Change in Muscle protein synthesis rate
Muscle synthesis protein rate calculated from deuterium incorporation into muscle tissue
24 weeks
Change in Muscle protein breakdown rate
Muscle protein breakdown rate calculated every 6 weeks using 3-methylhistidine tracer
24 weeks
Change in whole body fat volumes
Change in the amount of fat within the body, measured every 6 weeks using magnetic resonance imaging (MRI)
24 weeks
Change in liver fat volumes
Change in the amount of fat within the liver, measured every 6 weeks using magnetic resonance imaging (MRI)
24 weeks
Change in thigh muscle fat volumes
Change in the amount of fat within the vastus lateralis thigh muscle, measured every 6 weeks using magnetic resonance imaging (MRI)
24 weeks
Change in whole body muscle volumes
Change in the amount of muscle within the body, measured every 6 weeks using magnetic resonance imaging (MRI)
24 weeks
Change in muscle phosphocreatine synthesis rate
Change in the rate of phosphocreatine synthesis, measured every 6 weeks using magnetic resonance spectroscopy
24 weeks
Change in cerebral volume
Change in the volume of brain tissue, measured every 6 weeks using magnetic resonance imaging (MRI)
24 weeks
Change in cortical thickness
Change in the thickness of the brain cortex, measured every 6 weeks using magnetic resonance imaging (MRI)
24 weeks
Change in plasma metabolome
change in untargeted plasma metabolome profile measured every 6 weeks
24 weeks
Critères d'éligibilité

Âges éligibles
Adulte, Adulte âgé
Âge minimum
55 Years
Sexes éligibles
Tous
Accepte les volontaires en bonne santé
Oui
  • Group 1 ('non-sedentary') self-reporting <6 sedentary hrs/day, not actively involved in exercise training or a regular physical activity regimen (>8,000 steps/day).
  • Group 2 ('sedentary') self-reporting ≥8 waking hrs/day in sedentary activities and/or ≤5,000 steps/day.
  • Aged 55-65y.
  • Overweight (BMI 25-35 kg/m2).
  • Waist circumference ≥94cm (males) and ≥80cm (females).
  • Willing to alter physical activity levels as instructed for 6 months
  • Without neurological or psychiatric diseases, motor or cognitive restrictions
  • Ability to give informed consent

  • Regular medication use that could interfere with measures
  • A history, or evidence, of chronic cardiovascular, metabolic, musculoskeletal, renal or respiratory diseases.
  • Experiencing 'long-COVID', inflammatory bowel disease or malignancy.
  • Uncontrolled hypertension. Stage 1 hypertension (BP ≤160/100mmHg) with no other signs of cardiovascular disease, and blood pressure (BP) managed by routine medication will not be an exclusion.
  • People employed in jobs that would preclude reducing step count and night-shift workers.
  • Females who are pre/peri-menopausal, but stable on hormone replacement therapy is accepted (due to effect of oestrogen fluctuations on primary outcomes and the longitudinal study design).
  • Contraindications for MRI.
  • Allergy or sensitivity to local anaesthesia, or dressing adhesive
University of Nottingham logoUniversity of Nottingham
Biotechnology and Biological Sciences Research Council logoBiotechnology and Biological Sciences Research Council
Partie responsable de l'essai
Paul Greenhaff, Investigateur principal, Principal Investigator, University of Nottingham
Contact central de l'essai
Contact: Paul L Greenhaff (PI), PhD, +44 (0) 1158230133, [email protected]
Contact: Melanie Tooley (participant recruitment), BSc, +44 (0) 115 9515151, [email protected]
1 Centres de l'essai dans 1 pays

Notts

David Greenfield Human Physiology Unit, Nottingham, Notts, NG72UH, United Kingdom
Sara Brown, Contact, +44(0)115 8230434, [email protected]
Joanne Mallinson, PhD, Contact, +44(0)1158230434, [email protected]
Paul Greenhaff, PhD, Investigateur principal
Liz Simpson, PhD, Investigateur associé
Joanne Mallinson, PhD, Investigateur associé
Abhishek Sheth, MD, Investigateur associé
Penny Gowland, PhD, Investigateur associé
Sue Francis, PhD, Investigateur associé
Rosemary Nicholls, PhD, Investigateur associé
Sara Brown, Investigateur associé
Donald Peden, PhD, Investigateur associé
Alena Ponitzova, Investigateur associé
En recrutement